Cargando…
A pilot protocol to assess the feasibility of a virtual multiple crossover, randomized controlled trial design using methylphenidate in mild cognitive impairment
BACKGROUND: The conventional clinical trial design in Alzheimer’s disease (AD) and AD-related disorders (ADRDs) is the parallel-group randomized controlled trial. However, in heterogeneous disorders like AD/ADRDs, this design requires large sample sizes to detect meaningful effects in an “average” p...
Autores principales: | DesRuisseaux, Libby A., Williams, Victoria J., McManus, Alison J., Gupta, Anoopum S., Carlyle, Becky C., Azami, Hamed, Gerber, Jessica A., Bolling, Anna M., Cook, Carolyn L., Betensky, Rebecca A., Arnold, Steven E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729136/ https://www.ncbi.nlm.nih.gov/pubmed/33308285 http://dx.doi.org/10.1186/s13063-020-04752-x |
Ejemplares similares
-
Saving cognitive outcome data in Alzheimer's disease clinical trials during the COVID‐19 pandemic: Commentary on the virtual administration of the ADAS‐Cog
por: Schwab, Nadine A., et al.
Publicado: (2020) -
Présence empourprée
por: DesRuisseaux, Pierre, 1945-
Publicado: (1984) -
Detection of Oculomotor Dysmetria From Mobile Phone Video of the Horizontal Saccades Task Using Signal Processing and Machine Learning Approaches
por: AZAMI, HAMED, et al.
Publicado: (2022) -
The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial
por: Lion-François, Laurence, et al.
Publicado: (2014) -
Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease
por: Vallabh, Sonia M., et al.
Publicado: (2020)